Robert Seeger, MD, selected for award from Pediatric Blood and Marrow Transplant Consortium

February 23, 2016

Robert Seeger, MD, division head for Basic and Translational Research of the Center for Cancer and Blood Diseases at Children's Hospital Los Angeles (CHLA) has been selected for the 2016 Lifetime Achievement Award from the Pediatric Blood and Marrow Transplant Consortium (PBMC). As the eighth recipient of the prestigious award, Seeger is recognized for a career that exemplifies the mission of the PBMTC to support research and education to improve the availability, safety and efficacy of hematopoietic cell transplantation and other cellular therapeutics for children and adolescents.

Seeger, who has served as director of the Cancer Research Program in The Saban Research Institute of CHLA since 1995, has been at the forefront of cancer immunotherapy and genetics for decades. His therapeutic research deals with immunotherapy strategies that seek to maximize natural killer cell activity with tumor-cell targeting antibodies and with agents that modify the tumor microenvironment.

Few have had as much of an impact on the understanding and treatment of a single disease as Seeger has had on neuroblastoma - from his contributions to the creation of dinutuximab, to his work on genetically based risk stratification for neuroblastoma patients, to identifying and treating patients with residual neuroblastoma post-treatment.

In 2000, as part of his effort to expand therapeutic possibilities for neuroblastoma patients, he co-founded the New Approaches to Neuroblastoma Therapy (NANT) Consortium, which is based at CHLA.

In addition to being a world-class researcher, physician, author and advisor, Seeger is also professor of Pediatrics in the Keck School of Medicine of the University of Southern California and has made tremendous contributions to medical research by mentoring scientists and physicians who have become leaders in the field.

The PBMTC, now headquartered at CHLA, is the largest clinical trials group focused exclusively on blood and marrow transplants for children and adolescents. Under the leadership of Michael Pulsipher, MD, section head of Blood and Marrow Transplantation and Endowed Chair, BMT Clinical Research at CHLA, the consortium is comprised of more than 100 pediatric BMT centers in the United States, Canada, New Zealand and Australia, with affiliate members in Europe, South America and Southeast Asia.

The Lifetime Achievement Award was awarded to Seeger during the 2016 Tandem BMT Meetings of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research, held in Honolulu, Hawaii on February 19.
About Children's Hospital Los Angeles

Children's Hospital Los Angeles has been named the best children's hospital in California and among the top 10 in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children's Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California. For more information, visit Follow us on Twitter, Facebook, YouTube and LinkedIn, or visit our blog at

Children's Hospital Los Angeles

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to